Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Nectin-2 (CD112) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Nectin-2 (CD112) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). HEK293 Expressed (Native Glycosylation). Sequence Verified. |
View NECTIN2 Products |
| Gene Delivery | Nectin-2 (NECTIN2) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based binding assays. |
View NECTIN2 Products |
| Benchmark Ab | Anti-Nectin-2 Recombinant Monoclonal Antibody Recombinant positive control derived from clinical benchmark sequences. |
View NECTIN2 Products |
| Validator | Nectin-2 (NECTIN2) siRNA Set Target-specific knockdown verification in target-expressing tumor cells. |
View NECTIN2 Products |
| Related Target A | PVRIG (CD112R) The primary high-affinity inhibitory receptor for Nectin-2 on T and NK cells. |
View PVRIG Products |
| Related Target B | TIGIT Inhibitory receptor that shares the DNAM-1/PVR/Nectin-2 signaling axis. |
View TIGIT Products |
| Related Target C | CD155 (PVR) Homologous ligand sharing receptors (TIGIT, CD226) with Nectin-2, critical for selectivity profiling. |
View CD155 Products |
| Related Target D | CD226 (DNAM-1) The shared co-stimulatory activating receptor that competes with PVRIG and TIGIT for Nectin-2 binding. |
View CD226 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating PVRIG vs. TIGIT pathway blockade | Highly purified Nectin-2, PVRIG, and TIGIT recombinant proteins available for orthogonal ELISA/SPR screening. |
| Conformational integrity on target cells | NECTIN2 Lentivirus Premade Particles enable robust, stable surface expression for flow cytometry and cell-based blocking assays. |
| Lack of standardized controls | Clinical-grade Benchmark Antibodies (Biosimilars) available to calibrate assay sensitivity and binding kinetics. |
| Off-target assay noise | Sequence-verified siRNA validation sets ensure target specificity in phenotypic and functional assays. |
Live Nectin-2 (CD112) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Nectin-2/PVRIG pathway is emerging as a cornerstone of next-generation immune checkpoint blockade, particularly for patients refractory to PD-1/PD-L1 inhibitors. As a key ligand overexpressed across multiple solid tumors (including ovarian, endometrial, lung, and breast cancers), Nectin-2 interacts with the inhibitory receptor PVRIG (CD112R) and the activating receptor CD226 (DNAM-1). The clinical landscape is shifting from monotherapy to rational combinations, notably dual targeting of the PVRIG and TIGIT pathways to overcome compensatory immune escape mechanisms.
Competitive Modality & Indication Snapshot
Connecting clinical development trends directly to pre-clinical assay requirements:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Compugen, Bristol Myers Squibb, GSK | Ovarian Cancer, Endometrial Cancer, Solid Tumors | High-affinity blocking assays (Requires HEK293-expressed Nectin-2 ECD-Fc for native glycosylation). |
| Bispecific Antibodies (BsAbs) | Biotech Consortia | PD-1 Resistant Solid Tumors | Simultaneous binding assays (Requires dual-target screening panels: Nectin-2 / PVRIG / TIGIT). |
| Antibody-Drug Conjugates (ADCs) | Oncology Biopharma | Nectin-2 High-Expressing Epithelial Tumors | Internalization validation (Requires stable cell lines generated via NECTIN2 Lentivirus). |